Exane Derivatives’s Kura Oncology KURA Stock Holding History

Exane Derivatives’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,606	Closed	-$130K	–	1067
2021 Q1	$130K	Sell	4,606 -893	-16%	-$28.3K	0.04%	373
2020 Q4	$180K	Sell	5,499 -2,085	-27%	-$73.3K	0.05%	323
2020 Q3	$232K	Buy	7,584 +275	+4%	+$6.07K	0.07%	198
2020 Q2	$119K	Sell	7,309 -2,396	-25%	-$34.6K	0.03%	273
2020 Q1	$96.6K	Buy	+9,705	New	+$111K	0.03%	283

Other funds holding KURA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Exane Derivatives's KURA Position: Q2 2021 in Review

Exane Derivatives sold out of Kura Oncology (KURA) in Q2 2021, closing a stake of 4,606 shares — an estimated $130K sold.

Exane Derivatives first reported a position in KURA in Q1 2020 and held it in 5 quarters. The position peaked at $232K in Q3 2020. 171 funds tracked by Wall St. Rank hold KURA as of Q2 2021.

Exane Derivatives reported no remaining Kura Oncology position as of Q2 2021 after selling out during the quarter.
Exane Derivatives sold 4,606 Kura Oncology shares in Q2 2021, an estimated $130K.
Exane Derivatives first reported a position in Kura Oncology in Q1 2020 and held it in 5 quarters.
Exane Derivatives's Kura Oncology position peaked at $232K in Q3 2020.
171 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.